Presentation in London, stock up 8% in Milan today
Pixuvri, CTICs lead therapeutic candidate has been sold in Europe.
Pixuvri is the first approved treatment in the European Union in this patient setting. The decision cleared the way for CTI to market Pixuvri in the 27 Member States of the EU as well as in Iceland, Liechtenstein and Norway.
The European market could generate up to $240 million in annual revenue, once the company is able to penetrate the market, and successful use overseas could also bolster the company's prospects for US approval.